吉利德公司以50亿美元收购Tubulis, 以促进瘤管道的发展. Gilead to acquire Tubulis for $5B to boost oncology pipeline.

吉利德科学公司同意以50亿美元收购德国生物科技Tubulis, 以加强其瘤管道的新抗体-药物结合剂固体瘤. Gilead Sciences agreed to acquire German biotech Tubulis for $5 billion, aiming to strengthen its oncology pipeline with new antibody-drug conjugates for solid tumors. 这笔交易需要获得监管机构的批准, 凸显了吉利德向癌症治疗药物的战略转变, 并遵循生物制药领域整合趋势. The deal, subject to regulatory approval, underscores Gilead's strategic shift toward cancer therapeutics and follows a trend of consolidation in the biopharmaceutical sector.